This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1.RH Swift , EP Harrigan , JC Cappelleri , D Kramer , LP Chandler . Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 2002; 36(2): 87–95.
2.JP Lindenmayer , E Brown , RW Baker , etal. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res. 2004; 68(2–3): 331–337.
4.A Björkdahl , D Olsson , T Palmstierna . Nurses’ short-term prediction of violence in acute psychiatric intensive care. Acta Psychiatr Scand. 2006; 113(3): 224–229.
6.L Citrome , L Green . The dangerous agitated patient: what to do right now. Postgrad Med. 1990; 87(2): 231–236.
8.DA Regier , ME Farmer , DS Rae , etal. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990; 264(19): 2511–2518.
9.J Battaglia , S Moss , J Rush , etal. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997; 15(4): 335–340.
10.S Brook , JV Lucey , KP Gunn . Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis: Ziprasidone I.M. Study Group. J Clin Psychiatry. 2000; 61(12): 933–941.
11.DG Daniel , DL Zimbroff , RH Swift , EP Harrigan . The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol. 2004; 19(1): 9–15.
12.S Brook , J Walden , I Benattia , CO Siu , SJ Romano . Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl). 2005; 178(4): 514–523.
13.P Wright , K Meehan , M Birkett , etal. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther. 2003; 25(5): 1420–1428.
14.R Andrezina , RN Marcus , DA Oren , etal. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med Res Opin. 2006; 22(11): 2209–2219.
15.MD Lesem , JM Zajecka , RH Swift , KR Reeves , EP Harrigan . Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001; 62(1): 12–18.
16.DG Daniel , SG Potkin , KR Reeves , RH Swift , EP Harrigan . Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl). 2001; 155(2): 128–134.
17.L Citrome . Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007; 68(12): 1876–1885.
19.P Wright , M Birkett , SR David , etal. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001; 158(7): 1149–1151.
20.A Breier , K Meehan , M Birkett , etal. A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002; 59(5): 441–448.
21.K Meehan , F Zhang , S David , etal. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001; 21(4): 389–397.
22.KM Meehan , H Wang , SR David , etal. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002; 26(4): 494–504.
23.R Andrezina , RC Josiassen , RN Marcus , etal. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl). 2006; 188(3): 281–292.
24.TK Tran-Johnson , DA Sack , RN Marcus , etal. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007; 68(1): 111–119.
25.DL Zimbroff , RN Marcus , G Manos , etal. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. 2007; 27(2): 171–176.
26.SA Rappaport , RN Marcus , G Manos , RD McQuade , DA Oren . A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. J Am Med Dir Assoc. 2009; 10(1): 21–27.
27.MH Allen , D Feifel , MD Lesem , etal. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011; 72(10): 1313–1321.
28.MD Lesem , TK Tran-Johnson , RA Riesenberg , etal. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011; 198(1): 51–58.
29.J Kwentus , RA Riesenberg , M Marandi , etal. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012; 14(1): 31–40.
30.L Citrome . Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int J Clin Pract. 2012; 66(3): 318–325.
31.L Citrome . Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Ther Clin Risk Manag. 2013; 9: 235–245.
33.L Citrome . Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009; 63(12): 1762–1784.
35.MP Wilson , D Pepper , GW Currier , GH Holloman Jr, D Feifel . The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. West J Emerg Med. 2012; 13(1): 26–34.
36.J Volavka , L Citrome . Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract. 2008; 62(8): 1237–1245.
37.KA Nolan , J Volavka , P Czobor , etal. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J Psychiatr Res. 2005; 39(1): 109–115.
38.KA Nolan , J Volavka , P Mohr , P Czobor . Psychopathy and violent behavior among patients with schizophrenia or schizoaffective disorder. Psychiatr Serv. 1999; 50(6): 787–792.
39.DJ Cooke , C Michie . Refining the construct of psychopathy: towards a hierarchical model. Psychol Assess. 2001; 13(2): 171–188.
40.KA Nolan , P Czobor , BB Roy , etal. Characteristics of assaultive behavior among psychiatric inpatients. Psychiatr Serv. 2003; 54(7): 1012–1016.
41.L Citrome . New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013; 13(7): 767–783.
42.J Volavka , JM Zito , J Vitrai , P Czobor . Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol. 1993; 13(4): 287–289.
43.L Citrome , J Volavka , P Czobor , etal. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv. 2001; 52(11): 1510–1514.
44.J Volavka , P Czobor , K Nolan , etal. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol. 2004; 24(2): 225–228.
45.MI Krakowski , P Czobor , L Citrome , N Bark , TB Cooper . Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006; 63(6): 622–629.
47.J Volavka , P Czobor , EM Derks , etal; EUFEST Study Group.Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2011; 72(7): 955–961.
49.BJ Kinon , SM Roychowdhury , DR Milton , AL Hill . Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry. 2001; 62(Suppl 2): 17–21.
50.L Citrome , J Volavka . Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs. 2011; 25(12): 1009–1021.
51.L Citrome . Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother. 2009; 9(1): 55–71.
52.L Citrome , J Levine , B Allingham . Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv. 2000; 51(5): 634–638.
53.L Citrome , CB Shope , KA Nolan , P Czobor , J Volavka . Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol. 2007; 22(6): 356–362.
56.M Alpert , ER Allan , L Citrome , etal. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull. 1990; 26(3): 367–371.
57.N Caspi , I Modai , P Barak , etal. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol. 2001; 16(2): 111–115.